keyword
MENU ▼
Read by QxMD icon Read
search

Anthracycline

keyword
https://www.readbyqxmd.com/read/28210763/artemisinin-and-its-derivatives-in-cancer-therapy-status-of-progress-mechanism-of-action-and-future-perspectives
#1
REVIEW
Archana Bhaw-Luximon, Dhanjay Jhurry
Since the late 1990s, there has been rapid multiplication of data on the anti-cancer properties of artemisinins. This article reviews the status of progress of artemisinin and its derivatives as anti-cancer agents in clinical trials, case reports, and in vitro/in vivo studies. Particular attention is laid on the combinations of artemisinins and synthetic chemodrugs to enhance the latter's efficacy. An attempt is here made to rationalize the synergistic effects of a few common anti-cancer drugs of the anthracycline, taxane, anti-metabolite, and platinum-based drug families...
February 16, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28209298/utidelone-plus-capecitabine-versus-capecitabine-alone-for-heavily-pretreated-metastatic-breast-cancer-refractory-to-anthracyclines-and-taxanes-a-multicentre-open-label-superiority-phase-3-randomised-controlled-trial
#2
Pin Zhang, Tao Sun, Qingyuan Zhang, Zhongyu Yuan, Zefei Jiang, Xiao Jia Wang, Shude Cui, Yuee Teng, Xi-Chun Hu, Junlan Yang, Hongming Pan, Zhongsheng Tong, Huiping Li, Qiang Yao, Yongsheng Wang, Yongmei Yin, Ping Sun, Hong Zheng, Jing Cheng, Jinsong Lu, Baochun Zhang, Cuizhi Geng, Jian Liu, Roujun Peng, Min Yan, Shaohua Zhang, Jian Huang, Li Tang, Rongguo Qiu, Binghe Xu
BACKGROUND: Utidelone, a genetically engineered epothilone analogue, has shown promise as a potential treatment for breast cancer in phase 1 and 2 trials. The aim of this phase 3 trial was to compare the efficacy and safety of utidelone plus capecitabine versus capecitabine alone in patients with metastatic breast cancer. METHODS: We did a multicentre, open-label, superiority, phase 3, randomised controlled trial in 26 hospitals in China. Eligible participants were female patients with metastatic breast cancer refractory to anthracycline and taxane chemotherapy regimens...
February 10, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28196257/association-between-use-of-a-scalp-cooling-device-and-alopecia-after-chemotherapy-for-breast-cancer
#3
Hope S Rugo, Paula Klein, Susan Anitra Melin, Sara A Hurvitz, Michelle E Melisko, Anne Moore, Glen Park, Jules Mitchel, Erika Bågeman, Ralph B D'Agostino, Elizabeth S Ver Hoeve, Laura Esserman, Tessa Cigler
Importance: Chemotherapy-induced alopecia is a common and distressing adverse effect. In previous studies of scalp cooling to prevent chemotherapy-induced alopecia, conclusions have been limited. Objectives: To evaluate whether use of a scalp cooling system is associated with a lower amount of hair loss among women receiving specific chemotherapy regimens for early-stage breast cancer and to assess related changes in quality of life. Design, Setting, and Participants: A prospective cohort study conducted at 5 US medical centers of women with stage I or II breast cancer receiving adjuvant or neoadjuvant chemotherapy regimens excluding sequential or combination anthracycline and taxane (106 patients in the scalp cooling group and 16 in the control group; 14 matched by both age and chemotherapy regimen)...
February 14, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28196254/effect-of-a-scalp-cooling-device-on-alopecia-in-women-undergoing-chemotherapy-for-breast-cancer-the-scalp-randomized-clinical-trial
#4
Julie Nangia, Tao Wang, Cynthia Osborne, Polly Niravath, Kristen Otte, Steven Papish, Frankie Holmes, Jame Abraham, Mario Lacouture, Jay Courtright, Richard Paxman, Mari Rude, Susan Hilsenbeck, C Kent Osborne, Mothaffar Rimawi
Importance: Chemotherapy may induce alopecia. Although scalp cooling devices have been used to prevent this alopecia, efficacy has not been assessed in a randomized clinical trial. Objectives: To assess whether a scalp cooling device is effective at reducing chemotherapy-induced alopecia and to assess adverse treatment effects. Design, Setting, and Participants: Multicenter randomized clinical trial of women with breast cancer undergoing chemotherapy...
February 14, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28196134/alterations-in-estrogen-signalling-pathways-upon-acquisition-of-anthracycline-resistance-in-breast-tumor-cells
#5
Simon Chewchuk, Baoqing Guo, Amadeo Mark Parissenti
Intrinsic or acquired drug resistance is a major impediment to the successful treatment of women with breast cancer using chemotherapy. We have observed that MCF-7 breast tumor cells selected for resistance to doxorubicin or epirubicin (MCF-7DOX2 and MCF-7EPI cells, respectively) exhibited increased expression of several members of the aldo-keto reductase (AKR) gene family (in particular AKR1C3 and AKR1B10) relative to control MCF-7CC cells selected by propagation in the absence of drug. Normal cellular roles for the AKRs include the promotion of estrogen (E2) synthesis from estrone (E1) and the hydroxylation and detoxification of exogenous xenobiotics such as anthracycline chemotherapy drugs...
2017: PloS One
https://www.readbyqxmd.com/read/28194058/l-probe-a-novel-non-anthracycline-combination-chemotherapy-regimen-for-aggressive-b-cell-non-hodgkin-lymphoma-in-elderly-patients
#6
Arjun Datt Law, Gaurav Prakash, Alka Khadwal, Ashim Das, Subhash Varma, Pankaj Malhotra
The management of aggressive B cell lymphomas in elderly patients is associated with poor tolerability of commonly used chemotherapeutic agents. The safety and tolerability of a novel combination chemotherapy regimen utilizing rituximab, lenalidomide, bendamustine, vincristine and prednisolone was assessed in a series of elderly patients with new onset or relapsed/refractory aggressive B cell lymphoma and inability to receive conventional chemotherapy due to poor performance status and/or significant comorbidities...
March 2017: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/28191923/one-pot-combinatorial-biosynthesis-of-glycosylated-anthracyclines-by-co-cultivation-of-streptomyces-strains-producing-aglycones-and-nucleotide-deoxysugars
#7
Eunji Kim, Myoung Chong Song, Myoun Su Kim, Ji Yoon Beom, Jin A Jung, Hang Soo Cho, Yeo Joon Yoon
Anthracyclines such as doxorubicin are effective anticancer drugs composed of a tetracyclic polyketide aglycone and one or more deoxysugar moieties, which play a critical role in their biological activity. A facile one-pot combinatorial biosynthetic system was developed for the generation of a range of glycosylated derivatives of anthracyclines. Co-cultivation of Streptomyces venezuelae mutants producing two anthracycline aglycones with eight different nucleotide deoxysugar-producing S. venezuelae mutants that co-express a substrate-flexible glycosyltransferase led to the generation of sixteen aklavinone or ε-rhodomycinone glycosides containing diverse deoxysugar moieties, seven of which are new...
February 13, 2017: ACS Combinatorial Science
https://www.readbyqxmd.com/read/28191909/the-influence-of-chemotherapy-on-the-right-ventricle-did-we-forget-something
#8
REVIEW
Marijana Tadic, Cesare Cuspidi, Dagmara Hering, Lucia Venneri, Oleksandr Danylenko
BACKGROUND: A large number of chemotherapy-induced cardiovascular complications were discovered in studies over the last several decades. The focus of the majority of these studies was left ventricular (LV) remodeling. The aim of this article was to provide a comprehensive overview of potential mechanisms of chemotherapy-induced right ventricular (RV) remodeling and summarize clinical studies on this topic. HYPOTHESIS: Chemotherapy induces RV structural, functional, and mechanical changes...
February 13, 2017: Clinical Cardiology
https://www.readbyqxmd.com/read/28191807/neo-adjuvant-chemotherapy-in-locally-advanced-breast-cancer-a-retrospective-analysis-from-tertiary-care-centre
#9
Deepti Sharma, Garima Singh
INTRODUCTION: Breast cancer is the most common cancer in women in India. The incidence of LABC is 30%-40% in developing countries as compared to developed countries, lack of awareness and screening programmes in developing countries are supposed to be main contributor of this increase incidence. The use of neoadjuvant chemotherapy in locally advanced breast cancer has shown benefits in down staging of tumors, and increases the rate of breast conserving surgeries. AIM: The aim was to compare response rate (clinical and pathological), the disease free survival, and overall survival in two chemotherapy regime...
September 2016: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/28190761/prevalence-of-circulating-tumor-cells-after-adjuvant-chemotherapy-with-or-without-anthracyclines-in-patients-with-her2-negative-hormone-receptor-positive-early-breast-cancer
#10
Amelie Schramm, Fabienne Schochter, Thomas W P Friedl, Nikolaus de Gregorio, Ulrich Andergassen, Marianna Alunni-Fabbroni, Elisabeth Trapp, Bernadette Jaeger, Georg Heinrich, Oumar Camara, Thomas Decker, Angelika Ober, Sven Mahner, Tanja N Fehm, Klaus Pantel, Peter A Fasching, Andreas Schneeweiss, Wolfgang Janni, Brigitte K Rack
BACKGROUND: Use of anthracycline-based chemotherapy in patients with early breast cancer (EBC) has been well-established but is often associated with cardiotoxicity. Based on data suggesting a limited benefit of anthracyclines in human epidermal growth factor receptor 2 (HER2)-negative patients, the Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as well as Life Style Intervention Strategies (SUCCESS) C study randomized patients to either anthracycline-containing or anthracycline-free chemotherapy...
January 10, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28185035/anthracycline-chemotherapy-and-cardiotoxicity
#11
John V McGowan, Robin Chung, Angshuman Maulik, Izabela Piotrowska, J Malcolm Walker, Derek M Yellon
Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer. Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer survivor to increased cardiovascular morbidity and mortality. The basic mechanisms of cardiotoxicity may involve direct pathways for reactive oxygen species generation and topoisomerase 2 as well as other indirect pathways. Cardioprotective treatments are few and those that have been examined include renin angiotensin system blockade, beta blockers, or the iron chelator dexrazoxane...
February 9, 2017: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/28181130/micrornas-mir-7-and-mir-340-predict-response-to-neoadjuvant-chemotherapy-in-breast-cancer
#12
Mithu Raychaudhuri, Holger Bronger, Theresa Buchner, Marion Kiechle, Wilko Weichert, Stefanie Avril
PURPOSE: miRNAs have been linked to chemosensitivity of breast cancer cells in vitro. In patients, however, there is no clinically validated method for predicting chemotherapy response. The aim of this study was to assess whether (I) a specific pattern of miRNA expression in pretherapeutic biopsies can predict response to neoadjuvant chemotherapy, and (II) differential miRNA expression in residual tumor after completion of chemotherapy allows further prognostic stratification of non-responding patients...
February 8, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28179588/tp53-based-interaction-analysis-identifies-cis-eqtl-variants-for-tp53bp2-fbxo28-and-fam53a-that-associate-with-survival-and-treatment-outcome-in-breast-cancer
#13
Rainer Fagerholm, Sofia Khan, Marjanka K Schmidt, Montserrat García-Closas, Päivi Heikkilä, Jani Saarela, Jonathan Beesley, Maral Jamshidi, Kristiina Aittomäki, Jianjun Liu, H Raza Ali, Irene L Andrulis, Matthias W Beckmann, Sabine Behrens, Fiona M Blows, Hermann Brenner, Jenny Chang-Claude, Fergus J Couch, Kamila Czene, Peter A Fasching, Jonine Figueroa, Giuseppe Floris, Gord Glendon, Qi Guo, Per Hall, Emily Hallberg, Ute Hamann, Bernd Holleczek, Maartje J Hooning, John L Hopper, Agnes Jager, Maria Kabisch, Renske Keeman, Veli-Matti Kosma, Diether Lambrechts, Annika Lindblom, Arto Mannermaa, Sara Margolin, Elena Provenzano, Mitul Shah, Melissa C Southey, Joe Dennis, Michael Lush, Kyriaki Michailidou, Qin Wang, Manjeet K Bolla, Alison M Dunning, Douglas F Easton, Paul D P Pharoah, Georgia Chenevix-Trench, Carl Blomqvist, Heli Nevanlinna
TP53 overexpression is indicative of somatic TP53 mutations and associates with aggressive tumors and poor prognosis in breast cancer. We utilized a two-stage SNP association study to detect variants associated with breast cancer survival in a TP53-dependent manner. Initially, a genome-wide study (n = 575 cases) was conducted to discover candidate SNPs for genotyping and validation in the Breast Cancer Association Consortium (BCAC). The SNPs were then tested for interaction with tumor TP53 status (n = 4,610) and anthracycline treatment (n = 17,828)...
February 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/28174484/non-anthracycline-containing-docetaxel-and-cyclophosphamide-regimen-is-associated-with-sustained-worse-outcome-compared-with-docetaxel-anthracycline-and-cyclophosphamide-in-neoadjuvant-treatment-of-triple-negative-and-her2-positive-breast-cancer-patients-updated
#14
Xiaosong Chen, Guolin Ye, Chenfang Zhang, Xinzheng Li, Kunwei Shen
OBJECTIVE: A previous study demonstrated that non-anthracycline-containing docetaxel plus cyclophosphamide (TC) regimen was inferior to docetaxel, anthracycline and cyclophosphamide (TAC) in neoadjuvant treatment of triple-negative breast cancer (TNBC) and human epidermal growth factor receptor-2-(HER2)-positive breast cancer in a short-term follow-up. Herein, long-term follow-up survival outcomes have been investigated. METHODS: TNBC or HER2-positive patients were randomized to receive 6 cycles of TC or TAC neoadjuvant treatment...
December 2016: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
https://www.readbyqxmd.com/read/28174294/trastuzumab-in-human-epidermal-growth-factor-receptor-2-positive-early-breast-cancer-results-of-a-prospective-noninterventional-study-on-routine-treatment-between-2006-and-2012-in-germany
#15
Peter Dall, Thorsten Koch, Thomas Göhler, Johannes Selbach, Andreas Ammon, Jochen Eggert, Nidal Gazawi, Daniela Rezek, Arthur Wischnik, Carsten Hielscher, Stella Keitel, Ursula Cirrincione, Axel Hinke, Gabriele Feisel-Schwickardi
PURPOSE: Trastuzumab is part of the standard treatment in patients with human epidermal growth factor receptor 2-positive early breast cancer in addition to (neo)adjuvant chemotherapy. This German prospective noninterventional study, which included major patient cohorts underrepresented in the pivotal randomized studies, examined the generalizability of the results of those studies. PATIENTS AND METHODS: Between 2006 and 2012, 4,027 patients were enrolled and treated with trastuzumab; they were unselected regarding age or concomitant/sequential adjuvant chemotherapy...
February 7, 2017: Oncologist
https://www.readbyqxmd.com/read/28165571/negative-pressure-wound-therapy-and-early-pedicle-flap-reconstruction-of-the-chest-wall-after-epirubicin-extravasation
#16
Marios Papadakis, Afshin Rahmanian-Schwarz, Marzena Bednarek, Mohamed Arafkas, Philipp Holschneider, Gunnar Hübner
PURPOSE: Accidental extravasation is a serious iatrogenic injury among patients receiving anthracycline-containing chemotherapy. The aim of this work is to present a combination therapy for chest wall reconstruction following epirubicin extravasation. METHODS: Herein, we report a 68-year-old woman with massive soft tissue necrosis of the anterolateral chest wall after epirubicin extravasation from a port implanted in the subclavicular area. RESULTS: The necrotic tissue was resected, the port was removed, and negative-pressure wound therapy was applied...
January 31, 2017: Journal of Vascular Access
https://www.readbyqxmd.com/read/28161993/eribulin-in-non-small-cell-lung-cancer-challenges-and-potential-strategies
#17
Umang Swami, Umang Shah, Sanjay Goel
Eribulin is a non-taxane, macrocyclic, synthetic, ketone analog of Halichondrin B with a microtubule inhibitory action specific towards plus ends. It is approved by United States Food and Drug Administration (USFDA) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. It is also approved as a third line therapy for patients with metastatic breast cancer who have received a prior treatment with anthracycline and taxane in either adjuvant or metastatic setting...
February 6, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28157161/an-exploratory-study-to-determine-whether-brca1-and-brca2-mutation-carriers-have-higher-risk-of-cardiac-toxicity
#18
Monique Sajjad, Michael Fradley, Weihong Sun, Jongphil Kim, Xiuhua Zhao, Tuya Pal, Roohi Ismail-Khan
Anthracycline-based cardiotoxicity is concerning for women with breast cancer and portends a dose-dependent risk of developing left ventricular dysfunction. Overall, the prevalence of heart failure (HF) is ≈2% of the total US population; however, BRCA-deficient mice have shown increased HF. We evaluated for the inherent risk of HF in women with BRCA mutations to determine whether treatment with anthracycline-based therapy increased this risk. We obtained results on BRCA mutation carriers regarding cancer treatment and HF, identified through the BRCA patient advocacy organization Facing Our Risk for Cancer Empowered (FORCE) and the Moffittbased Inherited Cancer Registry...
2, 2017: Genes
https://www.readbyqxmd.com/read/28156636/rolapitant-for-the-prevention-of-nausea-in-patients-receiving-moderately-or-highly-emetogenic-chemotherapy
#19
Cindy K Nagy, Sujata Arora, Daniel Powers, Rebecca Anne Clark-Snow
: 224 Background: Nausea control remains an unmet need for patients receiving moderately or highly emetogenic chemotherapy (MEC, HEC). The objective of this analysis was to determine the effect of the neurokinin-1 (NK-1) receptor antagonist rolapitant (VARUBI) on the prevention of nausea in patients receiving either MEC or HEC. METHODS: Post hoc analyses of nausea from three randomized, double-blind, active-controlled, phase 3 clinical trials were performed for carboplatin-based MEC (n = 401), non-carboplatin-based MEC (n = 228), total MEC (n = 629), anthracycline/cyclophosphamide (AC)-based chemotherapy (n = 703), and cisplatin-based HEC (n = 1070)...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152932/national-comprehensive-cancer-network-petitions-submissions-and-outcomes
#20
Dinah Faith Huff, William J Hrushesky, Charles Lee Bennett, Kevin Knopf, Michael Baum
: 248 Background: The National Comprehensive Cancer Network (NCCN) invites petitions to its scientific panels. Most ( > 95%) are from the pharmaceutical industry lobbying to include their products in the NCCN Guidelines. Rarely, physicians request scientific scrutiny of the guidelines. We report the experience of Oncology Analytics (OA) with petition submissions and the possible impact on guidelines. METHODS: From 2011-2015, OA made 7 petitions to NCCN. The content of each was tracked into subsequent NCCN Guidelines to ascertain whether any changes resulted...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
12198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"